Femasys Inc cash flow statement
In fiscal 2025, Femasys Inc's operations generated −$18.7m of cash; it spent $525,007 on capital projects, leaving free cash flow of −$19.2m.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | −5 | −8 | −11 | −11 | −19 | −19 | −18 |
| Depreciation and amortisation | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Stock-based pay | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Capital spending | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Free cash flow | −5 | −8 | −11 | −11 | −20 | −19 | −18 |
| Free cash flow after stock pay | −5 | −8 | −11 | −12 | −21 | −20 | −19 |
| Share buybacks | — | — | 0 | 0 | 0 | — | — |
| Shares issued | 0 | 32 | 0 | 8 | 2 | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −5,475 | −5,075 | −4,765 | −4,353 | −5,387 | −4,185 | −4,144 | −3,936 |
| Depreciation and amortisation | 76 | 82 | 85 | 86 | 86 | 85 | 82 | 83 |
| Stock-based pay | 128 | 134 | 367 | 182 | 175 | 66 | 152 | 211 |
| Capital spending | 408 | 107 | 97 | 94 | 194 | 140 | 79 | 9 |
| Free cash flow | −5,883 | −5,181 | −4,862 | −4,447 | −5,582 | −4,325 | −4,223 | −3,945 |
| Free cash flow after stock pay | −6,011 | −5,316 | −5,229 | −4,629 | −5,756 | −4,392 | −4,374 | −4,156 |
| Shares issued | 1,022 | 1,003 | 5,392 | −882 | — | — | — | — |
Compare with peers
- Volitionrx LTD cash flow
- Seastar Medical Holding Corp cash flow
- Insight Molecular Diagnostics Inc. cash flow
- Icecure Medical Ltd. cash flow
- Cerenome, Inc. cash flow
Head to head: FEMY vs VNRXFEMY vs ICUFEMY vs IMDX
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies